跳到正文
原文
Endpoints News 生物医药· ENDPOINTS·· 2026-10-14AI 评分28

Ultragenyx 完成第二笔 PRV 交易;Biomea 口服 GLP-1 数据致股价大跌

Ultragenyx's second PRV sale; Biomea's oral GLP-1 data leads to stock slump

AI 导读

Ultragenyx Pharmaceutical 本月出售第二笔 PRV,该公司为商业化阶段的罕见病制药企业。Biomea 口服 GLP-1 数据公布后股价大幅

正文

Plus news about Sanofi, Pharm­ing, Sky­hook Bio and Al­tay Ther­a­peu­tics.

Ul­tragenyx Phar­ma­ceu­ti­cal sells sec­ond PRV this month: The com­mer­cial-stage rare dis­ease drug­mak­er sold its sec­ond …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news